1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
National Cancer Institute Youth Enjoy Science Research Education Program (R25 Clinical Trial Not Allowed) is sponsored by National Cancer Institute (NCI). This program supports research educational activities that encourage students (grades 6-12 and/or undergraduate) to become knowledgeable about cancer and to consider cancer research as a career path.
While not directly focused on breast cancer imaging AI validation, it is a cancer-related research education program that universities are eligible for.
Get alerted about grants like this
Get emailed when new opportunities from “National Cancer Institute (NCI)” or related funders appear. Free, weekly, unsubscribe anytime.
Or search similar grants →According to the current listing, eligibility includes: Eligible applicants include state governments, county governments, city or township governments, special district governments, independent school districts, public and state institutions of higher education, private institutions of higher education, federally recognized Native American tribal governments, other Native American tribal organizations, public and Indian housing authorities, non-profits, for-profit organizations, small businesses, and other eligible applicants as detailed in the NOFO. Confirm the full requirements in the official notice before applying.
Applications for National Cancer Institute Youth Enjoy Science Research Education Program (R25 Clinical Trial Not Allowed) are due September 28, 2026. Build your timeline backwards from this date to cover registrations, approvals, and final submission checks.
National Cancer Institute Youth Enjoy Science Research Education Program (R25 Clinical Trial Not Allowed) is funded by National Cancer Institute (NCI). Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
Past winners and funding trends for this program
NCI Continuing Umbrella of Research Experiences (CURE) Academic Career Excellence (ACE) Award (K32) is a grant from the National Cancer Institute (NCI) that funds early postdoctoral fellows from diverse backgrounds, including underrepresented groups, to pursue research training in cancer-related fields. The K32 award supports fellows within 12 months prior to transitioning into, or within the first two years of, a postdoctoral position. The program, operated through NCI's Center to Reduce Cancer Health Disparities (CRCHD), aims to enhance the pool of qualified diverse cancer researchers. Beginning with the June 12, 2025 due date, the CURE ACE Award is available in both Independent Clinical Trial Required and Independent Clinical Trial Not Allowed versions. Eligible applicants must be U.S. citizens or permanent residents at time of award.
Digital Health Technology Derived Biomarkers and Outcome Assessments for Remote Monitoring and Endpoint Development is sponsored by National Institutes of Health (NIH) / National Cancer Institute (NCI). This funding opportunity focuses on digital health approaches that can significantly advance the assessment, monitoring, and understanding of cancer risk factors and determinants and increase participant reach and engagement in cancer research.
This Funding Opportunity Announcement (FOA) invites Small Business Innovation Research (SBIR) grant applications from small business concerns (SBCs) for funding to perform research leading to the development of innovative technologies that may advance progress for early detection and assessment of individuals at risk and for early diagnosis, prognosis and follow-up of type 1 diabetes (T1D). Funding Opportunity Number: RFA-DK-15-024. Assistance Listing: 93.847. Funding Instrument: G. Category: FN,HL. Award Amount: $2M total program funding.
This initiative will stimulate and support innovative research by small business concerns that may lead to the development of novel technologies for the early diagnosis, monitoring and treatment of micro and macro vascular complications of diabetes which are associated with significant morbidity and mortality of the disease and high costs to the health care system. Funding Opportunity Number: PA-14-058. Assistance Listing: 93.847. Funding Instrument: G. Category: FN,HL.